Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, exerts antiepileptic effects via the GABA/benzodiazepine receptor complex in mice

• Published in: British journal of pharmacology 2011-11, Vol.164 (5), p.1534-1546
• Main Authors: Chen, CR, Tan, R, Qu, WM, Wu, Z, Wang, Y, Urade, Y, Huang, ZL
• Format: Article
• Language: English
• Subjects: Animals; Anticonvulsants - administration & dosage; Anticonvulsants - isolation & purification; Anticonvulsants - therapeutic use; Anticonvulsants. Antiepileptics. Antiparkinson agents; Behavior, Animal - drug effects; Biological and medical sciences; Biphenyl Compounds - administration & dosage; Biphenyl Compounds - isolation & purification; Biphenyl Compounds - therapeutic use; Cerebral Cortex - drug effects; Cerebral Cortex - metabolism; Dose-Response Relationship, Drug; EEG; Electroencephalography; epileptiform activity; Excitatory Postsynaptic Potentials - drug effects; flumazenil; GABA; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy; Hippocampus - drug effects; Hippocampus - metabolism; Lignans - administration & dosage; Lignans - isolation & purification; Lignans - therapeutic use; Magnolia; Magnolia - chemistry; magnolol; Male; Medical sciences; Mice; Mice, Inbred Strains; Molecular Structure; Nervous system (semeiology, syndromes); Neurology; Neuropharmacology; pentylenetetrazol; Pharmacology. Drug treatments; Plant Bark - chemistry; Receptors, GABA-A - metabolism; Research Papers; seizure; Seizures - drug therapy; Seizures - metabolism
• ISSN: 0007-1188; 1476-5381; 1476-5381
• DOI: 10.1111/j.1476-5381.2011.01456.x

BACKGROUND AND PURPOSE The aim of this study was to evaluate the anti‐convulsant effects of magnolol (6, 6′, 7, 12‐tetramethoxy‐2, 2′‐dimethyl‐1‐β‐berbaman, C18H18O2) and the mechanisms involved. EXPERIMENTAL APPROACH Mice were treated with magnolol (20, 40 and 80 mg·kg−1) 30 min before injection with pentylenetetrazol (PTZ, 60 mg·kg−1, i.p.). The anti‐seizure effects of magnolol were analysed using seizure models of behaviour, EEG and in vitro electrophysiology and c‐Fos expression in the hippocampus and cortex. KEY RESULTS Magnolol at doses of 40 and 80 mg·kg−1 significantly delayed the onset of myoclonic jerks and generalized clonic seizures, and decreased the seizure stage and mortality compared with those of the vehicle‐treated animals. EEG recordings showed that magnolol (40 and 80 mg·kg−1) prolonged the latency of seizure onset and decreased the number of seizure spikes. The anti‐epileptic effect of magnolol was reversed by the GABAA/benzodiazepine receptor antagonist flumazenil. Pretreatment with flumazenil decreased the effects of magnolol on prolongation of seizure latency and decline of seizure stage. In a Mg2+‐free model of epileptiform activity, using multi‐electrode array recordings in mouse hippocampal slices, magnolol decreased spontaneous epileptiform discharges. Magnolol also significantly decreased seizure‐induced Fos immunoreactivity in the piriform cortex, dentate gyrus and hippocampal area CA1. These effects were attenuated by pretreatment with flumazenil. CONCLUSIONS AND IMPLICATIONS These findings indicate that the inhibitory effects of magnolol on epileptiform activity were mediated by the GABAA/benzodiazepine receptor complex.